Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors

Autor: Herraez, Elisa, Al-Abdulla, Ruba, Soto, Meraris, Briz, Oscar, Bettinger, Dominik, Bantel, Heike, del Carmen, Sofia, Serrano, Maria A., Geier, Andreas, Marin, Jose J.G., Macias, Rocio I.R.

Publikováno v: In Biochemical Pharmacology November 2023 217

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of Alternative Splicing Variants on Liver Cancer Biology.

Autor: Marin JJG; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain., Reviejo M; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain., Soto M; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain., Lozano E; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain., Asensio M; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain., Ortiz-Rivero S; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain., Berasain C; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, 31008 Pamplona, Spain.; Hepatology Program, CIMA, University of Navarra, 31008 Pamplona, Spain., Avila MA; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, 31008 Pamplona, Spain.; Hepatology Program, CIMA, University of Navarra, 31008 Pamplona, Spain., Herraez E; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.

Publikováno v: Cancers [Cancers (Basel)] 2021 Dec 21; Vol. 14 (1). Date of Electronic Publication: 2021 Dec 21.